| Background:World Health Organization statistics, every year there are about10million new cancer patients, and about6-7million deaths. Our country also has a high incidence of cancer, according to the National Cancer Registry Center recently releasing 《2012Annual Report of Cancer Registration in China)), the new tumor cases nationwide each year is estimated at about3.12million cases, an average of8550people a day, every minute six people were diagnosis of malignancy. And the gradual aging of the population structure in our country, the proportion of suffering from cancer will increase higher. As establishment of biological-psychological-social medical model, improving and enhancing the quality of life of cancer patients has become increasingly important in designing cancer treatment. And because of the whole idea of the concept of traditional Chinese medicine, which emphasizes addressing both the symptoms and root cause, treatment of cancer patients by intervening traditional Chinese medicine receives more and more attention. Among them, acupuncture has its unique advantage and potential to improve the life quality of patients with cancer, but the related research is less compared with traditional Chinese medicine treatment. So this study takes Astragalus Injection in Zusanli point injection method, to study how to improve the quality of life of patients with tumor after chemotherapy by taxol.Objective:The purpose of this study was to Astragalus Injection in Zusanli point injection method, to investigate the quality of life of the patients with tumor after chemotherapy of paclitaxel, and provide new ideas and methods to improve the life quality of patients with tumors in clinic.Methods:This study used a randomized test methods, and cancer patients met the inclusion criteria were randomly divided into Astragalus Injection in Zusanli point injection combined with chemotherapy in the treatment group and the control group of conventional chemotherapy,30patients in each group. The treatment group used acupoint injection once a day, bilateral alternating, from patients before chemotherapy for1day to1days after chemotherapy for a course of treatment. The changes before treatment, after fifth days, Ninth days after treatment, the patients in each group to observe the total number of white blood cells, the hemoglobin, and the platelets respectively, inhibit the evaluation of bone marrow; and record using rhG-CSF times after the current cycle of chemotherapy. At the same time using the KPS score with the WHO table and the developed specifically for cancer patients quality of life scale QLQ-C30designed by the European Organization for Research and Treatment of Cancer (EORTC) for two groups of patients after chemotherapy scored the survival quality. Before treatment, the two groups do baseline compared with sex, age, disease and KPS score. Results:1. Evaluation of bone marrow suppression:The two group of white blood cells and hemoglobin bone marrow suppression occurred bone marrow inhibition in the middle of chemotherapy, but no significant difference(P>0.05). And in the chemotherapy later stage, the two groups still have bone marrow suppression, but the treatment group bone marrow inhibition’s degree was lower than control group, with significant difference(P<0.05). Two groups of platelet inhibition also have bone marrow myelosuppression in chemotherapy period, and the treatment group bone marrow inhibition’s level was lower than that of the control group, the difference was significant (P<0.05), but in the later chemotherapy two groups of bone marrow inhibition had no significant difference (P>0.05). At the same time, the treatment group using rhG-CSF times was significantly less than the control group, there was significant difference between two groups (P<0.05).2. KPS score:There was no big difference between the two groups’KPS score before chemotherapy, not statistically significant and comparable; after chemotherapy the KPS of the treatment group was significantly higher than that of control group, statistically significant differences (P<0.05).3. QLQ-C30quality of life score:In function score, the treatment group in the physical function scores was better than the control group, the difference was significant (P<0.05), two groups of scores in the role, emotional and social function had no difference (P>0.05). About symptom scale, the score of fatigue, nausea and vomiting, difficulty in breathing, loss of appetite, constipation and diarrhea in treatment group was lower than those in control group, with significant difference (P<0.05); and in pain, insomnia and economic scale, the difference between the two groups were not significantly (P>0.05). With the score in the general state of health, the treatment group was significantly better than the control group (P<0.05) Conclusion:1.Astragalus injection in Zusanli acupoint injection has protective and reduce the degree of inhibition to paclitaxel chemotherapy in patients with bone marrow.2.Astragalus injection in Zusanli acupoint injection can improve the quality of life of paclitaxel chemotherapy patients, especially in improving toxicity. |
PDF Full Text Request